Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
PAPA JOSEPH CDirector
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001242215-26-000014 · form4-06122026_040609.xml · derivative · entry 1 PAPA JOSEPH C · CIK 0001242215 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
Giles Lisa M.Director
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001568850-26-000002 · form4-06122026_040607.xml · derivative · entry 1 Giles Lisa M. · CIK 0001568850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
Fischer Seth H. Z.Director
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001573553-26-000002 · form4-06122026_040605.xml · derivative · entry 1 Fischer Seth H. Z. · CIK 0001573553 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
Wills Robert JamesDirector
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001634189-26-000002 · form4-06122026_040601.xml · derivative · entry 1 Wills Robert James · CIK 0001634189 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
Duty StuartDirector
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001970274-26-000004 · form4-06122026_040603.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
TOMSICEK MICHAEL JOHNDirector
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001570392-26-000003 · form4-06122026_040614.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC |
Saik AndrewDirector
|
GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001616284-26-000002 · form4-06122026_040612.xml · derivative · entry 1 Saik Andrew · CIK 0001616284 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 20:06 UTC |
Oliveto JosephDirector · President and CEO
|
SaleCommon Shares | 36,500 | $2.26 | $82,490.00 |
DisclosureSEC source: 0001437782-26-000010 · form4-04202026_080414.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 446,244 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 17:50 UTC |
Bharucha DavidChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001910985-26-000005 · form4-02042026_050203.xml · derivative · entry 2 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Shares · 136,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 17:50 UTC |
Bharucha DavidChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001910985-26-000005 · form4-02042026_050203.xml · derivative · entry 1 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC |
Oliveto JosephDirector · President and CEO
|
GrantRestricted Stock Unit · Derivative | 453,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437782-26-000006 · form4-02042026_050201.xml · derivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,000 Underlying: Common Shares · 453,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC |
Oliveto JosephDirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 679,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001437782-26-000006 · form4-02042026_050201.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,000 Underlying: Common Shares · 679,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:52 UTC |
Muller LorenzChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001771207-26-000004 · form4-02042026_100201.xml · derivative · entry 2 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Shares · 136,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:52 UTC |
Muller LorenzChief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001771207-26-000004 · form4-02042026_100201.xml · derivative · entry 1 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC |
Hasija AmitCFO & EVP of Corp. Development
|
GrantRestricted Stock Unit · Derivative | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787700-26-000004 · form4-02042026_100239.xml · derivative · entry 2 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Shares · 136,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC |
Hasija AmitCFO & EVP of Corp. Development
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001787700-26-000004 · form4-02042026_100239.xml · derivative · entry 1 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
GrantRestricted Stock Unit · Derivative | 136,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001943112-26-000004 · form4-02042026_050205.xml · derivative · entry 2 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Shares · 136,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. F3 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 22:50 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001943112-26-000004 · form4-02042026_050205.xml · derivative · entry 1 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 16:30 UTC Amendment |
Bharucha DavidChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001910985-26-000006 · form4a-02052026_040214.xml · derivative · entry 1 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 21:30 UTC Amendment |
Oliveto JosephDirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 679,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001437782-26-000007 · form4a-02052026_040217.xml · derivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 679,000 Underlying: Common Shares · 679,000 shares Expires 2036-02-02 F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 21:30 UTC Amendment |
Nelson Jeffrey EdwardChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001943112-26-000005 · form4a-02052026_040212.xml · derivative · entry 1 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 21:30 UTC Amendment |
Muller LorenzChief Commercial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001771207-26-000005 · form4a-02052026_040210.xml · derivative · entry 1 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 21:30 UTC Amendment |
Hasija AmitCFO & EVP of Corp. Development
|
GrantEmployee Stock Option (right to buy) · Derivative | 204,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001787700-26-000005 · form4a-02052026_040208.xml · derivative · entry 1 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Shares · 204,000 shares Expires 2036-02-02 F1 · derivative.exercise_price: The exercise price on the initial filings was incorrectly stated. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 18:30 UTC |
Bharucha DavidChief Medical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001910985-26-000003 · form4-01282026_060109.xml · derivative · entry 6 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,300 Underlying: Common Shares · 20,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 18:30 UTC |
Bharucha DavidChief Medical Officer
|
SaleCommon Shares | 12,245 | $1.93 | $23,632.85 |
DisclosureSEC source: 0001910985-26-000003 · form4-01282026_060109.xml · nonDerivative · entry 4 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,181 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 18:30 UTC |
Bharucha DavidChief Medical Officer
|
Exercise / conversionCommon Shares | 20,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001910985-26-000003 · form4-01282026_060109.xml · nonDerivative · entry 3 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each RSU represents a contingent right to receive one common share. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Oliveto JosephDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 66,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · derivative · entry 6 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,800 Underlying: Common Shares · 66,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Oliveto JosephDirector · President and CEO
|
SaleCommon Shares | 34,523 | $1.93 | $66,629.39 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 4 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,744 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Oliveto JosephDirector · President and CEO
|
Exercise / conversionCommon Shares | 66,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 3 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each RSU represents a contingent right to receive one common share. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001943112-26-000002 · form4-01282026_060107.xml · derivative · entry 6 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,300 Underlying: Common Shares · 20,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
SaleCommon Shares | 12,245 | $1.93 | $23,632.85 |
DisclosureSEC source: 0001943112-26-000002 · form4-01282026_060107.xml · nonDerivative · entry 4 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,848 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
Exercise / conversionCommon Shares | 20,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001943112-26-000002 · form4-01282026_060107.xml · nonDerivative · entry 3 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each RSU represents a contingent right to receive one common share. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Muller LorenzChief Commercial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001771207-26-000002 · form4-01282026_060105.xml · derivative · entry 6 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,300 Underlying: Common Shares · 20,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Muller LorenzChief Commercial Officer
|
SaleCommon Shares | 11,180 | $1.93 | $21,577.40 |
DisclosureSEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 4 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,406 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Muller LorenzChief Commercial Officer
|
Exercise / conversionCommon Shares | 20,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 3 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each RSU represents a contingent right to receive one common share. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Hasija AmitCFO & EVP of Corp. Development
|
Exercise / conversionRestricted Stock Units · Derivative | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001787700-26-000002 · form4-01282026_060103.xml · derivative · entry 6 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,300 Underlying: Common Shares · 20,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one common share. F7 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. F7 · derivative.expiration_date: One-fourth (1/4th) of the shares subject to the RSU award vested or will vest on each of January 26, 2026, January 26, 2027, January 26, 2028 and January 26, 2029, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Hasija AmitCFO & EVP of Corp. Development
|
SaleCommon Shares | 12,245 | $1.93 | $23,632.85 |
DisclosureSEC source: 0001787700-26-000002 · form4-01282026_060103.xml · nonDerivative · entry 4 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,848 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 23:30 UTC |
Hasija AmitCFO & EVP of Corp. Development
|
Exercise / conversionCommon Shares | 20,100 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001787700-26-000002 · form4-01282026_060103.xml · nonDerivative · entry 3 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,093 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each RSU represents a contingent right to receive one common share. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 21:53 UTC |
Oliveto JosephDirector · President and CEO
|
SaleCommon Shares | 43,000 | $2.25 | $96,750.00 |
DisclosureSEC source: 0001437782-26-000002 · form4-01092026_090136.xml · nonDerivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,721 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:53 UTC |
Oliveto JosephDirector · President and CEO
|
SaleCommon Shares | 500 | $2.25 | $1,125.00 |
DisclosureSEC source: 0001437782-26-000002 · form4-01092026_090136.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,721 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025. Read SEC document |
| December 15, 2025 Filed Jan 28, 2026 18:30 UTC |
Bharucha DavidChief Medical Officer
|
SaleCommon Shares | 58,007 | $2.32 | $134,576.24 |
DisclosureSEC source: 0001910985-26-000003 · form4-01282026_060109.xml · nonDerivative · entry 2 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,326 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Jan 28, 2026 23:30 UTC |
Oliveto JosephDirector · President and CEO
|
SaleCommon Shares | 133,054 | $2.32 | $308,685.28 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 2 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,667 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Jan 28, 2026 23:30 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
SaleCommon Shares | 58,007 | $2.32 | $134,576.24 |
DisclosureSEC source: 0001943112-26-000002 · form4-01282026_060107.xml · nonDerivative · entry 2 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,993 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Jan 28, 2026 23:30 UTC |
Muller LorenzChief Commercial Officer
|
SaleCommon Shares | 53,566 | $2.32 | $124,273.12 |
DisclosureSEC source: 0001771207-26-000002 · form4-01282026_060105.xml · nonDerivative · entry 2 Muller Lorenz · CIK 0001771207 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,486 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2025 Filed Jan 28, 2026 23:30 UTC |
Hasija AmitCFO & EVP of Corp. Development
|
SaleCommon Shares | 58,007 | $2.32 | $134,576.24 |
DisclosureSEC source: 0001787700-26-000002 · form4-01282026_060103.xml · nonDerivative · entry 2 Hasija Amit · CIK 0001787700 · CFO & EVP of Corp. Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,993 F3 · kind: Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of PSUs or restricted stock unit ("RSU") awards only, respectively. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 18:30 UTC |
Bharucha DavidChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001910985-26-000003 · form4-01282026_060109.xml · derivative · entry 5 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2034-05-06 F6 · derivative.exercise_date: 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 18:30 UTC |
Bharucha DavidChief Medical Officer
|
GrantCommon Shares | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001910985-26-000003 · form4-01282026_060109.xml · nonDerivative · entry 1 Bharucha David · CIK 0001910985 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,333 F1 · shares: Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil). F2 · price: Each PSU represents a contingent right to receive one common share. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 23:30 UTC |
Oliveto JosephDirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · derivative · entry 5 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 280,000 shares Expires 2034-05-06 F6 · derivative.exercise_date: 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 23:30 UTC |
Oliveto JosephDirector · President and CEO
|
GrantCommon Shares | 280,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437782-26-000004 · form4-01282026_060101.xml · nonDerivative · entry 1 Oliveto Joseph · CIK 0001437782 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 583,721 F1 · shares: Represents a performance stock unit ("PSU") award that vested upon the certification by the Compensation Committee of the Board of Directors of the Issuer that the U.S. Food and Drug Administration has provided a New Drug Application Approval Letter granting approval of Cardamyst (etripamil). F2 · price: Each PSU represents a contingent right to receive one common share. Read SEC document |
| December 12, 2025 Filed Jan 28, 2026 23:30 UTC |
Nelson Jeffrey EdwardChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001943112-26-000002 · form4-01282026_060107.xml · derivative · entry 5 Nelson Jeffrey Edward · CIK 0001943112 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2034-05-06 F6 · derivative.exercise_date: 50% of the option will vest on June 12, 2026 and 50% will vest on December 12, 2026, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.